ArticlePloS one2025
Signatures of tumor microenvironment-related genes and long noncoding RNAs predict poor prognosis in osteosarcoma.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- An international framework for clinical translation of molecular classifiers in osteosarcoma.NPJ precision oncology · 2026Article
- Review
- Article
- GeneCytNet: an interpretable deep learning framework for rheumatoid arthritis classification andFrontiers in immunology · 2026Article
Corrections and comments
- Expression of concern
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOsteosarcoma is an aggressive bone cancer with poor outcomes, especially in young individuals. This study sought to identify tumor microenvironment-related genes (TMIEGs) and associated long noncoding RNAs (TMIELs) that influence patient prognosis. MATERIALS AND
methodsData from the TARGET osteosarcoma and GTEx muscle datasets were analysed to calculate stromal and immune scores, dividing patients into high- and low-score groups. Differential gene expression was assessed, and prognostic TMIELs and TMIEGs were identified through regression analyses. Prognostic signatures were evaluated via Kaplan‒Meier curves, receiver operating characteristic (ROC) analysis, and Cox regression, while immune cell composition was analysed via CIBERSORT.
resultsThree prognostic TMIELs (AC090559.1, LINC01549, SENCR) and three TMIEGs (DOK2, RHBDL2, NPW) were identified. High-risk patients have poorer survival outcomes, with immune processes possibly reducing the risk of osteosarcoma. Prognostic signatures effectively predict overall survival.
conclusionTMIEGs and TMIELs can reliably predict survival in patients with osteosarcoma, suggesting their potential as therapeutic biomarkers and the need for further research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.